Vepdegestrant and Encorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Encorafenib
Vepdegestrant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced vepdegestrant exposure, reduced efficacy of vepdegestrant, an increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmia symptoms
Interaction Deep Dive
Avoid coadministration of vepdegestrant and QT interval prolonging agents as it may reduce vepdegestrant exposure, which may reduce efficacy of vepdegestrant. It may also result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including torsade de pointes, other serious arrhythmias, and sudden death. If unavoidable, obtain ECGs when initiating and during concomitant use, and as clinically indicated. In patients with QTc greater than 480 ms or greater than 60 ms increase from baseline: Withhold vepdegestrant until QTc less than or equal to 480 ms and less than or equal to 60 ms above baseline. Treat reversible causes, then resume vepdegestrant at the same dose. Initiate more frequent ECG monitoring. In patients with QTc greater than 500 ms: Withhold vepdegestrant until QTc less than or equal to 480 ms and less than 60 ms above baseline. If a reversible cause is identified and corrected, resume vepdegestrant at the same dose. If no reversible cause is identified, resume vepdegestrant at a reduced dose. Increase ECG monitoring and permanently discontinue vepdegestrant, if QTc greater than 500 ms recurs. In patients that develop torsade de pointes, polymorphic ventricular tachycardia, or serious arrhythmia symptoms: Permanently discontinue vepdegestrant. Avoid concomitant use of vepdegestrant with strong CYP3A inducers in patients receiving vepdegestrant 100 mg or 200 mg once daily. If concomitant use cannot be avoided, increase vepdegestrant from 200 mg once daily to 300 mg once daily. After a CYP3A inducer has been discontinued for 7 to 14 days, resume vepdegestrant 200 mg once daily1.
Why it happens (mechanism)
Induction of CYP3A-mediated metabolism of vepdegestrant; additive QT interval prolongation
Literature reports
1 report — tap to read
a) In a drug interaction studies, concomitant use of vepdegestrant with carBAMazepine (strong CYP3A inducer) 200 mg three times daily resulted in reduced AUC by 64% and Cmax by 80% 1.
Common questions
Can I take Vepdegestrant and Encorafenib together?
Reduced vepdegestrant exposure, reduced efficacy of vepdegestrant, an increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmia symptoms Always confirm with your pharmacist or prescriber before making any change.
How serious is the Vepdegestrant and Encorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Vepdegestrant or Encorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VEPPANU oral tablet, vepdegestrant oral tablet. Pfizer Inc. New York, NY, 2026. DailyMed
Keep reading about Encorafenib
Keep reading about Vepdegestrant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist